Equities

Vistin Pharma ASA

Vistin Pharma ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)25.00
  • Today's Change0.10 / 0.40%
  • Shares traded22.18k
  • 1 Year change+12.61%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Vistin Pharma ASA share price to fall to 10.90 in the next year from the last price of 25.00.
High-56.4%10.90
Med-56.4%10.90
Low-56.4%10.90

Earnings history & estimates in NOK

Earnings forecasts are not available for Vistin Pharma ASA. On Feb 19, 2019, Vistin Pharma ASA reported 4th quarter 2018 losses of -- per share.
Average growth rate-89.88%
Annual earnings information is not available for Vistin Pharma ASA.
Average growth rate+202.59%
More ▼

Revenue history & estimates in NOK

Vistin Pharma ASA had 4th quarter 2018 revenues of 40.15m. This was 58.70% below the prior year's 4th quarter results.
Average growth rate+0.89%
Vistin Pharma ASA had revenues for the full year 2018 of 198.99m. This was 12.62% above the prior year's results.
Average growth rate+12.41%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.